Department of Physiology and Neurobiology, University of Connecticut, Storrs, CT, USA.
Lieber Institute for Brain Development, Johns Hopkins Medical Campus, Baltimore, MD, 21205, USA.
Nat Commun. 2021 Oct 13;12(1):5962. doi: 10.1038/s41467-021-26263-2.
Pitt-Hopkins syndrome (PTHS) is a rare autism spectrum-like disorder characterized by intellectual disability, developmental delays, and breathing problems involving episodes of hyperventilation followed by apnea. PTHS is caused by functional haploinsufficiency of the gene encoding transcription factor 4 (Tcf4). Despite the severity of this disease, mechanisms contributing to PTHS behavioral abnormalities are not well understood. Here, we show that a Tcf4 truncation (Tcf4) mouse model of PTHS exhibits breathing problems similar to PTHS patients. This behavioral deficit is associated with selective loss of putative expiratory parafacial neurons and compromised function of neurons in the retrotrapezoid nucleus that regulate breathing in response to tissue CO/H. We also show that central Nav1.8 channels can be targeted pharmacologically to improve respiratory function at the cellular and behavioral levels in Tcf4 mice, thus establishing Nav1.8 as a high priority target with therapeutic potential in PTHS.
皮特-霍普金斯综合征(PTHS)是一种罕见的自闭症谱系障碍,其特征为智力障碍、发育迟缓以及呼吸问题,包括过度通气后呼吸暂停发作。PTHS 是由转录因子 4(Tcf4)基因功能单倍不足引起的。尽管这种疾病很严重,但导致 PTHS 行为异常的机制仍不清楚。在这里,我们展示了 Tcf4 截断(Tcf4)的 PTHS 小鼠模型表现出类似于 PTHS 患者的呼吸问题。这种行为缺陷与假定呼气旁面神经神经元的选择性缺失以及调节组织 CO/H 反应呼吸的延髓背侧核神经元功能受损有关。我们还表明,可以通过药理学靶向中枢 Nav1.8 通道来改善 Tcf4 小鼠的细胞和行为水平的呼吸功能,从而将 Nav1.8 确立为 PTHS 具有治疗潜力的高度优先靶点。